CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 100 enrolled
Drug / intervention
BI 1744 (Olodaterol) Low Dose +3 moredrug
Likely dose
Foradil 12 mcgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00932646
NCT00932646Phase 3Completed
CompareCT.gov

Characterization of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Foradil in Patients With Chronic Obstructive Pulmonary Disease

Boehringer Ingelheim·interventional·Posted Jul 3, 2009·Updated Feb 5, 2016

In Brief

A Phase 3 clinical trial evaluating BI 1744 (Olodaterol) Low Dose, BI 1744 (Olodaterol) Medium Dose, and 2 other interventions for Pulmonary Disease, Chronic Obstructive. Completed, enrolled 100 participants across 13 sites.

Detailed Summary

The study is intended to characterize the lung function profile of BI1744 in COPD patients where patients will perform pulmonary function tests at regular intervals for 24 hours at the end of a 6 week treatment period. Each patient will receive all four treatments.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPulmonary Disease, Chronic Obstructive
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedJul 3, 2009
Enrollment StartJun 1, 2009
Primary CompletionMay 1, 2010
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 17.0 years ago

Interventions

BI 1744 (Olodaterol) Low Dosedrug

BI1744 Respimat low dose once daily and placebo Foradil

BI 1744 (Olodaterol) Medium Dosedrug

BI1744 Respimat medium dose once daily and placebo Foradil

Placebodrug

Placebo Respimat once daily and placebo Foradil

Foradildrug

12 mcg twice daily and placebo Respimat